Nisa Investment Advisors LLC increased its holdings in shares of Novartis AG (NYSE:NVS – Free Report) by 95.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,022 shares of the company’s stock after acquiring an additional 500 shares during the period. Nisa Investment Advisors LLC’s holdings in Novartis were worth $99,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of NVS. Fisher Asset Management LLC grew its stake in shares of Novartis by 15.7% during the 3rd quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock worth $196,225,000 after purchasing an additional 231,851 shares during the period. FMR LLC grew its position in Novartis by 5.5% during the third quarter. FMR LLC now owns 1,353,412 shares of the company’s stock worth $155,669,000 after buying an additional 70,314 shares during the period. Natixis Advisors LLC grew its position in Novartis by 2.9% during the third quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock worth $107,986,000 after buying an additional 26,317 shares during the period. Bank of Montreal Can increased its holdings in Novartis by 18.7% in the third quarter. Bank of Montreal Can now owns 780,980 shares of the company’s stock valued at $90,289,000 after buying an additional 123,077 shares in the last quarter. Finally, Creative Planning lifted its position in shares of Novartis by 4.1% during the 3rd quarter. Creative Planning now owns 344,951 shares of the company’s stock valued at $39,676,000 after acquiring an additional 13,486 shares during the period. Hedge funds and other institutional investors own 13.12% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on NVS. StockNews.com downgraded Novartis from a “strong-buy” rating to a “buy” rating in a research note on Friday. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Finally, BMO Capital Markets lifted their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Novartis currently has an average rating of “Hold” and a consensus price target of $123.38.
Novartis Trading Up 2.0 %
Novartis stock opened at $104.99 on Friday. The stock has a market cap of $214.61 billion, a PE ratio of 12.19, a P/E/G ratio of 1.42 and a beta of 0.57. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The stock has a 50-day moving average price of $100.07 and a 200 day moving average price of $108.53. Novartis AG has a 52 week low of $92.35 and a 52 week high of $120.92.
Novartis (NYSE:NVS – Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same quarter in the previous year, the business posted $1.74 earnings per share. Equities research analysts predict that Novartis AG will post 7.62 earnings per share for the current fiscal year.
Novartis Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Stories
- Five stocks we like better than Novartis
- How to Invest in Blue Chip Stocks
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- What Investors Need to Know About Upcoming IPOs
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Investing In Preferred Stock vs. Common Stock
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.